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2052atherosclerotic cardiovascular disease (ASCVD),
there is an entire section on nonstatins, including
the following paragraph on page 2913 in Section
6.3.2 of the guideline.
Clinicians treating high-risk patients who have a
less-than-anticipated response to statins, who are
unable to tolerate a less-than-recommended in-
tensity of a statin, or who are completely statin
intolerant, may consider the addition of a nonstatin
cholesterol-lowering therapy. High-risk individuals
include those with ASCVD, those with LDL-C $190
mg/dl, and those with diabetes 40–75 years of age. In
this situation, this guideline recommends clinicians
preferentially prescribe drugs that have been shown
in RCTs to provide ASCVD risk-reduction beneﬁts
that outweigh the potential for adverse effects and
drug-drug interactions and consider patient prefer-
ences (2).
This not an inconsequential point. In recent
randomized controlled trials (RCTs), niacin and
ezetemibe, when added to intensive statin therapy,
both lowered low-density lipoprotein cholesterol
(LDL-C), but the addition of niacin did not result in
improved outcomes and was associated with safety
issues (3,4). This is contrasted with a recently
reported RCT in a high-risk acute coronary syn-
drome population with 1 high-risk feature, where
addition of ezetemibe to a moderate-intensity statin
was shown to be both safe and incrementally
effective (5).
Second, they incorrectly state what the guide-
lines say about follow-up therapy. Although the
guidelines no longer endorse arbitrary LDL-C goals,
we are uncertain how the authors could infer
that the guidelines require little or no follow-up
therapy.
Figure 5, entitled “Monitoring Therapeutic Res-
ponse and Adherence,” and associated text on pages
2912 to 2913 indicate that the guidelines endorse
follow-up lipids, especially LDL-C. Follow-up lipids
are needed to not only determine attainment of the
therapeutic response to the appropriate intensity of
statin, but also to monitor adherence to statin and
lifestyle therapy.
Both of these errors are serious threats to the
appropriate use of this evidence-based guideline.
We respectfully request that Maddox et al. submit
an erratum to the journal to correct these inac-
curate statements regarding the 2013 American
College of Cardiology/American Heart Association
guideline on the treatment of blood cholesterol to
reduce the risk of atherosclerotic cardiovascular
risk in adults.*Neil J. Stone, MD, MACP
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REPLY: Getting Guidelines CorrectTheir Evidence-Based Recommendations for Use of
Nonstatins Added to Statins and the Need for Follow-Up
Lipid TestingWe appreciate the comments made by Dr. Stone
and colleagues regarding our paper discussing impli-
cations of the 2013 American College of Cardiology/
American Heart Association cholesterol guidelines (1).
As Dr. Stone and colleagues correctly point out, the
guidelines did not forbid nonstatin lipid-lowering
therapies, but rather suggested that clinicians “may
consider the addition of a nonstatin cholesterol-
lowering therapy” (1). At the time of the guideline
release and our paper publication, there were no
randomized, controlled trials (RCTs) that had dem-
onstrated cardiovascular (CV) event reduction be-
neﬁt with nonstatin lipid-lowering medications.
Thus, our statements indicating that these nonstatin
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for CV event reduction and our consequent conclu-
sions suggesting that the guidelines might lead to
signiﬁcant decreases in nonstatin use were consistent
with both the most current evidence at the time and
the guidelines (2).
We appreciate the added clariﬁcation provided by
the guideline authors, and note that their stated
preference for drugs proven to reduce CV events is
especially germane in the wake of the recently
released IMPROVE-IT (IMProved Reduction of Out-
comes: Vytorin Efﬁcacy International Trial) trial,
which demonstrated CV event reduction with ezeti-
mibe (3). This new information, available after the
release of both the 2013 guidelines and our paper, will
have implications for cholesterol management, and
we are currently exploring those in a new analysis of
PINNACLE (Practice Innovation and Clinical Excel-
lence) data.
We also recognize that the guidelines recom-
mended low-density lipoprotein cholesterol (LDL-C)
testing to assess appropriateness of statin response
and medication adherence. However, our paper did
not suggest that no LDL-C testing should occur
under the new guidelines, but rather that “the
new guidelines did not recommend treatment to
target LDL-C lipid levels, thus rendering repeated on-
treatment testing unnecessary” (italics our own) (2).
Under prior guidelines, repeated LDL-C testing to
determine whether a particular LDL-C target was
achieved took place with regularity, a phenomenon
that we demonstrated in our analysis and almost
certainly under-reported, given the frequency with
which LDL-C levels are checked by primary care pro-
viders (who were not included in our analysis).
Thus, our conclusion that “the cost and inconve-
nience of repeated LDL-C testing to titrate statin
medication to speciﬁc LDL-C targets would be
reduced” is consistent with the guidelines (2).
We appreciate the added clariﬁcation provided by
the guideline authors, and feel that it helps further
provide guidance to clinicians seeking to optimize
cholesterol management, and its attendant effects on
CV event reduction, for their patients.*Thomas M. Maddox, MD, MSc
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Beta-Blocker Variability
in Treatment of
Long QT SyndromeWhat Is the Confounder?We read with great interest the observational study
of patients with long QT syndrome (LQTS) by Abu-
Zeitone et al. (1) published in a recent issue of the
Journal. The key points noted by the authors
include equal efﬁcacy of 4 beta-blockers in the
general LQTS population in reducing the risk of ﬁrst
cardiac event; however, in patients with LQT2,
nadolol appeared to be the only one with signiﬁcant
risk reduction. In the high-risk patients with cardiac
events while on beta-blocker therapy, propranolol
was found to be the least effective (1). This study
was conducted in the background of studies impli-
cating propranolol as having a higher propensity to
block wild-type hERG (human ether-a-go-go related
gene) channel, which is involved in the pathogen-
esis of LQT2 (2); and differed from a recent study
showing no difference in the efﬁcacy of different
beta-blockers in preventing cardiac events in a
smaller sample of LQTS patients (3).
In the existing literature on beta-blockers spanning
more than half a century, there has been no major
study demonstrating a difference in efﬁcacy of beta-
blockers in heart rate reduction. Hence, we believe
that measuring heart rate pre- and post-use of beta-
blockers can be an effective surrogate marker of
appropriate dosing and compliance. The authors do
mention in their study limitations that registry data-
base provides reasonably reliable information about
patient compliance; however, no mention has been
made about the heart rate response on the different
